Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Huth who wrote (242)	11/24/1998 8:55:00 AM
From: yosi s	Respond to of 1386

If hu211 get approved than the stock will move very rapidly as there is no competition . If HU211 does not make it . than it all rest on how well the eye medication can support Pharmos and its future research.

To: Richard Huth who wrote (242)	11/24/1998 9:03:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1386

Richard, you're right, except that the SNX-111 trial termination was not announced widely. I never saw a press release. I found out through a BioCentury piece on the trial. Most investors will not be aware of this. So, I doubt that it will have much of an effect on the short term. In addition, the current market valuation of PARS gives very little value to HU-211. Look at the price prior to the Phase II results release and after. There is very little change. This suggests that the overall market already expects HU-211 to fail. If an expectation of success were there, PARS would be at $8-$10 per share right now. IMHO HU-211 will not be valued by the market until a major Pharma partner is signed up. Large investors want to see an endorsement of the technology by a respected established company before they are willing to establish positions. After all, few large investors really understand biotech, the science underlying it, or the medical conditions that are being addressed. They want to see analyst recommendations and partnerships to reassure them that the drug is for real and not just more biotech hype. This will happen with HU-211. But, not till a partner is announced. John de C